Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Small Cell Lung Cancer Extensive Stage

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States

    Contact: Study coordinator (Jennifer Hege) · jennifer.hege@usoncology.com
    Contact: Principal Investigator (Robert M Jotte, MD)
  • Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri, United States

    Contact: Study coordinator (Medical Oncology Clinical Call Center) · MedicalOncologyClinicalCallCenter@dom.wustl.edu · 314-747-1171
    Contact: Principal Investigator (Daniel Morgensztern, MD)
  • Gabrail Cancer Center Research, Canton, Ohio, United States

    Contact: Study coordinator (Carrie Smith) · csmith@gabrailcancercenter.com · 330-417-8231
    Contact: Study coordinator (Kim Roby) · kroby@gabrailcancercenter.com · 330.492.3345
    Contact: Principal Investigator (Nashat Gabrail, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Fairfield, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Willamette Valley Cancer Institute (Oregon), Eugene, Oregon, United States

    Contact: Study coordinator (Jeanne Schaffer) · jeanne.schaffer@usoncology.com
    Contact: Principal Investigator (Bo Wang, MD)
  • Northwest Cancer Specialists, P.C., Portland, Oregon, United States

    Contact: Study coordinator (Jennifer Thompson) · Jennifer.Thompson@usoncology.com
    Contact: Principal Investigator (Anthony Van Ho, MD)
  • Providence Cancer Institute, Portland, Oregon, United States

    Contact: Study coordinator (Brenda Fisher, RN) · canrsrchstudies@providence.org · 503-215-1979
    Contact: Principal Investigator (Rachel Sanborn, MD)
  • Northwest Cancer Specialists, P.C., Portland, Oregon, United States

    Contact: Study coordinator (Jennifer Thompson) · Jennifer.Thompson@usoncology.com
    Contact: Principal Investigator (Anthony Van Ho, MD)
  • Northwest Cancer Specialists, P.C., Tigard, Oregon, United States

    Contact: Study coordinator (Jennifer Thompson) · Jennifer.Thompson@usoncology.com
    Contact: Principal Investigator (Anthony Van Ho, MD)
  • Texas Oncology - DFW, Dallas, Texas, United States

    Contact: Study coordinator (Christine Terraciano) · Christine.terraciano@usoncology.com
    Contact: Principal Investigator (Kartik Konduri, MD)
  • Texas Oncology - Northeast Texas, Tyler, Texas, United States

    Contact: Study coordinator (Shelly Maxfield) · shelly.maxfield@usoncology.com
    Contact: Principal Investigator (Donald A Richards, MD)
  • Virginia Cancer Specialists, PC, Fairfax, Virginia, United States

    Contact: Study coordinator (Carrie Friedman) · carrie.friedman@usoncology.com
    Contact: Principal Investigator (Alexander I Spira, MD)
  • Northwest Cancer Specialists, P.C., Vancouver, Washington, United States

Study leads
  • Mark S Berger, MD

    Study Director

    Genprex, Inc.